Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer

Okabayashi, Takehiro; Shima, Yasuo; Iwata, Jun; Morita, Sojiro; Sumiyoshi, Tatsuaki; Sui, Kenta; Shimada, Yasuhiro; Iiyama, Tatsuo

doi:10.21873/anticanres.12176

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported on adjuvant chemotherapy for BTC [10,11,15,[18][19][20][21][22][23][24][25][26]. The multicentre randomized phase III trial PRODIGE 12-ACCORD 18 conducted by a French group failed to show the efficacy of gemcitabine and oxaliplatin (GEMOX) in treating BTC patients in an adjuvant setting [10].…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of S-1 as adjuvant chemotherapy is well established for gastric cancer [4] and pancreatic cancer [9]. Regarding BTC, some studies showed that adjuvant S-1 improved the prognosis [14,15]. Given that S-1 contains the 5-fluorouracil (5-FU) prodrug tegafur [13], previous studies using 5-FU as adjuvant chemotherapy for BTC [21,23] have also suggested the potential efficacy of S-1.…”

Section: Discussionmentioning

confidence: 99%

“…The benefit of S-1 as an adjuvant chemotherapy has been reported for gastric cancer [4] and pancreatic cancer [9]. For BTC, several studies have shown that the efficacy of S-1 adjuvant chemotherapy varies [14,15], and its effectiveness remains debatable.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis

Miyata

Kogure

Nakazawa

et al. 2021

JCM

View full text Add to dashboard Cite

Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, p = 0.033; OS, not available vs. 28.2 months, p = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion (p < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis

Miyata

Kogure

Nakazawa

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma

Luvira

Satitkarnmanee

Pugkhem

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Essential updates to the surgical treatment of biliary tract cancer

Matsukuma

Tokumitsu

Shindo

et al. 2019

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Biliary tract cancer, which includes intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, and ampullary cancer, is an intractable disease with a dismal prognosis. Prognosis is particularly poor in cases involving vessels or lymph nodes. Hepatobiliary pancreatic surgeons worldwide have consistently focused on improving surgical treatment, perioperative management, and chemotherapy to improve the outcomes of these diseases. There has been significant progress even in the last 2 years (2017 and 2018), such as promising findings reported by studies on the optimal extent of surgical treatment and multi‐institutional randomized controlled trials on adjuvant chemotherapy. We overview the current trends and advancements made in surgical treatment in 2017 and 2018.

show abstract

Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer

Abstract: We recommend the use of adjuvant S-1 therapy in patients with lymph node metastases or microvascular invasion.

Cited by 3 publications

References 22 publications

The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis

The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma

Essential updates to the surgical treatment of biliary tract cancer

Contact Info

Product

Resources

About